Long-term Failure Patterns and Survival in a Randomized Dose-escalation Trial for Prostate Cancer. Who Dies of Disease?

Abstract

radiation-induced subcutaneous fibrosis was found in 8 patients (5%) with a slight difference in disfavor of arm B (7%) vs 4% in arm A. Three patients (2%) presented a grade 2 pneumonitis (all in arm A). Overall, quality of life and cosmesis were good to excellent. Conclusions: Concurrent or sequential adjuvant radiohormonotherapy with letrozole is feasible in daily practice. Identifying hypersensitive patients with CD8 RIA or ATM screening will help tailoring treatments and details will be presented at the congress.

CD44 is a biomarker associated with human prostate cancer radiation sensitivity

“…Radiotherapy, especially external beam irradiation therapy (EBRT) is one of the major curative treatment options for localized prostate cancer (CaP) [1]. Several randomized trials have proved benefit of dose escalation to [ 70 Gy with EBRT for localized CaP [2][3][4]. Eade et al [5] recommend doses of [ or = 80 Gy for most men with CaP due to significant benefit for patients' outcome.…”

Therapieoptionen für Patienten mit Niedrigrisiko-Prostatakarzinom

“…Inzwischen wurde durch eine Reihe randomisierter Phase-III-Studien zur Erhöhung der Gesamtdosis einer 3D-konformalen Strahlentherapie der signifikante Vorteil der Dosiseskalation hinsichtlich des biochemisch und klinisch progressionsfreien Überlebens nachgewiesen [3, 11,24,30,41]. In einer 2009 publizierten Metaanalyse von 7 randomisierten Studien zur Dosiseskalation waren allerdings die gastrointestinalen Spätfolgen nach Dosiseskalation im Vergleich zur konventionell dosierten Strahlentherapie signifikant erhöht [35].…”

“…Inzwischen wurden die Daten von 5 randomisierten Studien zur Hypofraktionierung publiziert [1, 2, 18,24,29,31,38]. Die bislang erreichten Nachbeobachtungszeiten bis ca.…”

Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era

“…Looking at the long-term results of a dose-escalation trial [63], even in an high-dose arm (78 Gy) a PSA recurrence occurs in 21% of patients in the high-risk group with 8% of local recurrence and 4% of nodal and distant progression. Thus, even with high-dose RT, high-risk disease demands ADT.…”